Current Report Filing (8-k)

Date : 06/12/2019 @ 2:03PM
Source : Edgar (US Regulatory)
Stock : Bioxytran Inc (QB) (BIXT)
Quote : 0.3  0.07605 (33.96%) @ 3:28PM

Current Report Filing (8-k)

 

  

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

   

FORM 8-K

    

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 11, 2019

 

BIOXYTRAN, INC.

(Exact Name if Business Issuer as specified in its Charter)

  

Nevada   001-35027   26-2797630
(State or other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer
Identification Number)

  

233 Needham Street, 
Suite 300

Newton MA, 02464

(Address of principal executive offices, including zip code)

 

(617) 494-1199

(Registrant’s telephone number including area code)

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 1 4a- 12 under the Exchange Act (17 CFR 240.1 4a- 12)

 

Pre-commencement communications pursuant to Rule 1 4d-2(b) under the Exchange Act (17 CFR 240.1 4d-2(b))

 

Pre-commencement communications pursuant to Rule 1 3e-4(c) under the Exchange Act (17 CFR 240.1 3e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001   BIXT   OTC(Pink)

 

 

 

 

 

 

Item 1.01. Entry Into a Material Definitive Agreement.

  

On June 11, 2019, Bioxytran, Inc. (“Bioxytran”) and Steven entered into a Board Agreement (the “Agreement”) whereby Steven Aust (“Advisor”) will serve as a member of Bioxytran’s Advisory Board.  Advisor will advise Bioxytran will advise the Company from time to time on strategic planning to build awareness of the Company’s technology. The term of the Agreement is three months, renewable for two additional three-month terms or as extended by the Board of Directors of the Company and as agreed to in writing by Bioxytran and the Advisor.

 

As compensation for his services, Bioxytran will issue Advisor 250,000 shares of Bioxytran’s common stock, par value $0.01 per share (the “Common Stock”) upon the execution of the Agreement and at the beginning of each of the two additional three month term the Agreement is renewed for a maximum of up to 750,000 shares of Common Stock. In the event that the Agreement is renewed for a second term, the term will be extended for a period of one year and Mr. Aust will be solely compensated $20,000 per month. In addition, Bioxytran will pay for Advisor’s pre-approved expenses. The Agreement may be terminated by either party with 15 days prior written notice. Upon termination of the Agreement, Advisor shall receive payment for services performed and expenses paid or incurred. The Agreement also contains protection for Bioxytran’s intellectual property and confidential information. Advisor is an independent contractor and is not entitled to any employee benefits.

 

The foregoing description of the Scientific Advisory Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the form of Advisory Board Agreement, which is filed as Exhibit 10.25 to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 8.01. Other Events.

 

On June 12, 2019, Bioxytran issued a press release, “Bioxytran, Inc. Announces Public Company Executive Steve Aust to Join Advisory Board”

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit Number   Description
10.25   Form of Advisory Board Agreement between Bioxytran, Inc. and Steven Aust dated June 11, 2019.
     
99.1   Press Release dated June 12, 2019.

 

1

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

  By: /s/ Dr. David Platt
  Name: Dr. David Platt
  Title: President and Chief Executive Officer
   
 

Dated:

June 12, 2019

 

 

2

 

 

Bioxytran (QB) (USOTC:BIXT)
Historical Stock Chart

1 Year : From Apr 2019 to Apr 2020

Click Here for more Bioxytran (QB) Charts.

Bioxytran (QB) (USOTC:BIXT)
Intraday Stock Chart

Today : Wednesday 8 April 2020

Click Here for more Bioxytran (QB) Charts.

Latest BIXT Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.